Lonza Group AG

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 16:30:08 17/07/2024 BST			5-day change	1st Jan Change
509.2 ^CHF	-0.97%		-0.16%	+43.96%

07-03	Lonza Group Names New CEO	MT
07-02	Lonza Group AG Announces CEO Changes	CI

Lonza Group AG Plans to Invest CHF 14 Million to Expand Antibody Drug Conjugate Manufacturing Capacity in Visp, Switzerland

January 08, 2013 at 06:31 am

Lonza Group AG announced plans to invest CHF 14 million to expand Antibody Drug Conjugate (ADC) manufacturing capacity in Visp, Switzerland.

Latest news about Lonza Group AG

Lonza Group Names New CEO	07-03	MT
Lonza Group AG Announces CEO Changes	07-02	CI
Lonza Group's New CEO Assumes Role	07-01	MT
Berenberg Lifts Price Target on Lonza Group, Maintains Buy Recommendation	06-20	MT
Swiss Market Index Edges Up Ahead of Inflation Report	05-14	MT
Global markets live: Apple, Sony, Vodafone, Booking, Walmart...	05-14
Transcript : Lonza Group AG, Q1 2024 Earnings Call, May 14, 2024	05-14
Lonza Backs Guidance Despite Soft Start to Year	05-14	DJ
Lonza Affirms FY24 Sales Outlook, Raises Mid-term Growth Guidance	05-14	MT
Lonza Group AG Announces Board Changes	05-10	CI
Lonza Group AG Approves Cash Dividend, Payable on May 15, 2024	05-10	CI
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	04-18
Lonza Finance Launches EUR1 Billion 12-Year Euro Bond	04-18	DJ
Switzerland's Lonza Group Prices EUR1 Billion Bond	04-18	MT
NeuroSense Therapeutics Ltd. Collaborates with Lonza to Identify Exosome-Based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics	04-09	CI
Lonza Enters Manufacturing Agreement for Acumen’s Alzheimer’s Disease Drug Candidate	04-04	MT
Acumen Pharmaceuticals, Inc. Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer?S Disease	04-04	CI
Health Care Down on Flight From Risk -- Health Care Roundup	04-02	DJ
Indices: Five Magnificents instead of Seven	04-02
Global markets live: UBS, AT&T, Tesla, United Airlines, Humana, Wanda...	04-02
Lonza Group Appoints New CEO; Seeks Lifting of Trading Halt	04-02	MT
Lonza Taps Siegfried Holding's Wolfgang Wienand as Next CEO	04-02	DJ
Siegfried CEO Steps Down; Finance Chief Named Interim CEO	04-02	MT
Lonza Group Poaches Siegfried's CEO	04-02	MT
Lonza Group AG Announces Chief Executive Officer Changes	04-02	CI

Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (55.4%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (17.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.4%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (10.4%); - other (3.5%). Net sales are distributed geographically as follows: Switzerland (17.4%), Europe (31.7%), the United States (31.8%), the Americas (3.2%), Japan (8.1%), Asia (7.5%) and other (0.3%).

Sector

Biotechnology & Medical Research

Calendar

24/07/2024 - Q2 2024 Earnings Release

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

LONZA GROUP : Some mixed real-world effects

February 06, 2024 at 03:44 pm

More Strategies

Ratings for Lonza Group AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

514.2 CHF

Average target price

586 CHF

Spread / Average Target

+13.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
LONZA GROUP AG	+43.96%	41.47B
MODERNA, INC.	+24.47%	47.96B
IQVIA HOLDINGS INC.	+0.39%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+26.14%	31.6B
ICON PUBLIC LIMITED COMPANY	+20.25%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+51.67%	14.56B
MEDPACE HOLDINGS, INC.	+44.57%	14.14B
BIO-TECHNE CORPORATION	+2.11%	12.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.57%	11.71B

Other Biotechnology & Medical Research

Lonza Group AG

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Lonza Group AG Plans to Invest CHF 14 Million to Expand Antibody Drug Conjugate Manufacturing Capacity in Visp, Switzerland

Latest news about Lonza Group AG

Chart Lonza Group AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Lonza Group AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research